L‐Deprenyl in the Treatment of Mild Dementia of the Alzheimer Type: Preliminary Results

William J. Burke, Anthony E. Ranno, W. H. Roccaforte, Steven P. Wengel, Barbara L. Bayer, Nancy K. Willcockson

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Objective: To examine the short‐term cognitive and behavioral effects of L‐deprenyl in persons with mild dementia of the Alzheimer type (DAT) over a 2‐month period. Design: A 15‐month randomized, double‐blind, placebo‐controlled trial using a parallel‐group design. This report deals with the first 2 months of the trial. Participants: 39 subjects with mild DAT (CDR 1) selected using NINCDS‐ADRDA criteria. Measures: A battery of neuropsychological tests and clinical rating scales. Results: The placebo and L‐deprenyl subjects were similar at baseline on the clinical and neuropsychological tests. There was no evidence of a L‐deprenyl effect on any clinical or neuropsychological measures after 2 months. Conclusion: L‐deprenyl did not have a measurable impact on behavior or cognitive function over a 2‐month period in this group of subjects with mild DAT. 1993 The American Geriatrics Society

Original languageEnglish (US)
Pages (from-to)367-370
Number of pages4
JournalJournal of the American Geriatrics Society
Issue number4
StatePublished - Apr 1993

ASJC Scopus subject areas

  • Geriatrics and Gerontology


Dive into the research topics of 'L‐Deprenyl in the Treatment of Mild Dementia of the Alzheimer Type: Preliminary Results'. Together they form a unique fingerprint.

Cite this